2. Apoptosis
  3. Apoptosis
  4. 13-Methyltetradecanoic acid

13-Methyltetradecanoic acid  (Synonyms: 13-MTD; 13-Methylmyristic acid)

Cat. No.: HY-131503 Purity: 99.83%
SDS COA Handling Instructions

Molarity Calculator

13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells.

For research use only. We do not sell to patients.

13-Methyltetradecanoic acid Chemical Structure

13-Methyltetradecanoic acid Chemical Structure

CAS No. : 2485-71-4

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 13-Methyltetradecanoic acid:

13-Methyltetradecanoic acid Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

13-Methyltetradecanoic acid (13-MTD), a saturated branched-chain fatty acid with potent anticancer effects. 13-Methyltetradecanoic acid induces apoptosis in many types of human cancer cells[1][2].

In Vitro

13-Methyltetradecanoic acid (13-MTD; 0-140 μg/mL; 12-24 hours) inhibits cell viability and proliferation in human bladder cancer cells by inducing apoptosis[1].
13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2-48 hours) treatments results in significant accumulation of cells with sub-G1 DNA content in a time-dependent manner, with the proportion of sub-G1 phase DNA content ranging from 9.25% to 85.3% over 2-48 hours[1].
13-Methyltetradecanoic acid (13-MTD; 70 μg/mL; 2-24 hours) down-regulates Bcl-2 and up-regulates Bax. This promotes mitochondrial dysfunction, leading to the release of cytochrome c from the mitochondria to the cytoplasm, as well as the proteolytic activation of caspases. 13-Methyltetradecanoic acid down-regulates AKT phosphorylation and activates phosphorylation of p38 and c-Jun N-terminal kinase (JNK)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

13-Methyltetradecanoic acid Related Antibodies

Cell Viability Assay[1]

Cell Line: Bladder cancer cell lines T24, 5637, and UM-UC-3
Concentration: 0 μg/mL, 35 μg/mL, 70 μg/mL, 105 μg/mL, and 140 μg/mL
Incubation Time: 12 hours, 24 hours
Result: Inhibition of cell viability in a dose- and time-dependent manner.

Cell Cycle Analysis[1]

Cell Line: Bladder cancer cell lines T24, 5637, and UM-UC-3
Concentration: 70 μg/mL
Incubation Time: 2 hours, 8 hours, 24 hours, or 48 hours
Result: Resulted in significant accumulation of cells with sub-G1 DNA content in a time-dependent manner.

Western Blot Analysis[1]

Cell Line: T24, 5637, and UM-UC-3 cells
Concentration: 70 μg/mL
Incubation Time: 2 hours, 8 hours, 24 hours
Result: Down-regulated Bcl-2 and up-regulated Bax, and down-regulated AKT phosphorylation and activated phosphorylation of p38 and c-Jun N-terminal kinase (JNK).
In Vivo

13-Methyltetradecanoic acid (13-MTD; 70 mg/kg/day; oral gavage; daily; for 30 days) significantly suppresses tumor growth in a xenograft model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/C nude mice injected with Jurkat lymphoma cells[2]
Dosage: 70 mg/kg/day
Administration: Oral gavage; daily; for 30 days
Result: Effectively inhibited the growth in vivo in a xenograft model.
Molecular Weight

242.40

Formula

C15H30O2
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC(C)CCCCCCCCCCCC(O)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

Ethanol : ≥ 100 mg/mL (412.54 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.1254 mL 20.6271 mL 41.2541 mL
5 mM 0.8251 mL 4.1254 mL 8.2508 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% EtOH    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% EtOH    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (10.31 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.83%

SDS (393 KB)

COA (238 KB) RP-HPLC (238 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
Ethanol 1 mM 4.1254 mL 20.6271 mL 41.2541 mL 103.1353 mL
5 mM 0.8251 mL 4.1254 mL 8.2508 mL 20.6271 mL
10 mM 0.4125 mL 2.0627 mL 4.1254 mL 10.3135 mL
15 mM 0.2750 mL 1.3751 mL 2.7503 mL 6.8757 mL
20 mM 0.2063 mL 1.0314 mL 2.0627 mL 5.1568 mL
25 mM 0.1650 mL 0.8251 mL 1.6502 mL 4.1254 mL
30 mM 0.1375 mL 0.6876 mL 1.3751 mL 3.4378 mL
40 mM 0.1031 mL 0.5157 mL 1.0314 mL 2.5784 mL
50 mM 0.0825 mL 0.4125 mL 0.8251 mL 2.0627 mL
60 mM 0.0688 mL 0.3438 mL 0.6876 mL 1.7189 mL
80 mM 0.0516 mL 0.2578 mL 0.5157 mL 1.2892 mL
100 mM 0.0413 mL 0.2063 mL 0.4125 mL 1.0314 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

13-Methyltetradecanoic acid Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

13-Methyltetradecanoic acid2485-71-413-MTD 13-Methylmyristic acidApoptosisBcl-2Baxcytochrome-cp-p38AKTphosphorylationapoptosissaturatedbranched-chainInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
13-Methyltetradecanoic acid
Cat. No.:
HY-131503
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.